Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03706430 · ClinicalTrials.gov registry record
Validation of RPVi as a Parameter to Predict Fluid Responsiveness
A clinical trial, sponsored by Masimo Corporation.
- Terminated
- Registry status
- 63
- Enrollment target
NCT03706430: Clinical Trial study, sponsored by Masimo Corporation.
NCT03706430 is a clinical trial that was terminated before completion, run by Masimo Corporation. The registered enrollment target is 63 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03706430 was terminated before completion, sponsored by Masimo Corporation.
- TERMINATED
- Registry status
- 63 participants
- Enrollment target
Study Summary
This is a prospective, nonrandomized, sequential data collection study to evaluate the ability of RPVi to predict fluid responsiveness in comparison with other dynamic parameters including stroke volume variation (SVV) and/or pulse pressure variation (PPV).
Primary Outcome
To evaluate the ability of RPVi to predict fluid responsiveness in comparison with other dynamic parameters including Stroke Volume Variation (SVV) and/or Pulse Pressure Variation (PPV) using Bland Altman analysis.
Interventions
- DEVICE Pulse CO-Oximeter sensor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2018-09-24 |
| Est. Completion | 2021-10-20 |
Why NCT03706430 stopped before completion
NCT03706430 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 63 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Pulse CO-Oximeter sensor is the first listed.
NCT03706430 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03706430 about?
NCT03706430 is a clinical study titled "Validation of RPVi as a Parameter to Predict Fluid Responsiveness". This is a prospective, nonrandomized, sequential data collection study to evaluate the ability of RPVi to predict fluid responsiveness in comparison with other dynamic parameters including stroke volume variation (SVV) and/or pulse pressure variation (PPV).
What is the current status of trial NCT03706430?
This trial is currently terminated. The enrollment target is 63 participants. The study started on 2018-09-24. Estimated completion is 2021-10-20.
What interventions are being tested in trial NCT03706430?
The interventions under investigation include: Pulse CO-Oximeter sensor (DEVICE).
Who is sponsoring clinical trial NCT03706430?
This trial is sponsored by Masimo Corporation, which has 96 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03383575 · 63 participants · Phase 2
Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
- NCT04870944 · 63 participants · Phase 1
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
- NCT05031897 · 63 participants · Phase 2
Two Step Haplo With Radiation Conditioning
- NCT05312671 · 63 participants · Phase 2
Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI